Page last updated: 2024-08-21

fluorobenzenes and Hyperlipidemias

fluorobenzenes has been researched along with Hyperlipidemias in 106 studies

Research

Studies (106)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	74 (69.81)	29.6817
2010's	32 (30.19)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Balfagón, G; Ballesteros, S; Benito, M; Blanco-Rivero, J; Cachofeiro, V; de las Heras, N; Gómez-Hernández, A; Lahera, V; Martín-Fernández, B; Valero-Muñoz, M	1
Balu, S; Montouchet, C; Ruff, L	1
Chen, J; Chen, XJ; Cheng, L; Chu, JJ; Tang, XF; Zhang, XF	1
Akturk, E; Altas, Y; Atas, H; Balta, S; Can, C; Demirkol, S; Erdem, K; Korkmaz, H; Kurtoglu, E; Sincer, I; Yilmaz, M	1
Aloe, A; Carresi, C; Gliozzi, M; Gratteri, S; Janda, E; Mollace, V; Muscoli, C; Muscoli, S; Musolino, V; Palma, E; Ragusa, S; Romeo, F; Russo, V; Vitale, C; Walker, R	1
Ge, J; Wang, Z	1
Damasceno, NR; Fonseca, FA; Gidlund, M; Helfenstein, T; Izar, MC; Monteiro, AM; Moreira, FT; Neto, AM; Ramos, SC	1
An, T; Hayashi, H; Kikkawa, A; Kose, E; Matsumoto, Y	1
Liu, Y; Ren, L; Wang, P; Wang, Z; Ye, H; Zhao, N	1
Adams, SP; Sekhon, SS; Wright, JM	1
Elisaf, MS; Kostapanos, MS; Lagos, KG; Milionis, HJ; Rizos, CB; Tselepis, AD	1
Durrington, P; Soran, H	1
Filippatos, T; Milionis, HJ	1
Ai, M; Jones, PH; Matthan, NR; Otokozawa, S; Resteghini, NA; Schaefer, EJ; Stein, EA; van Himbergen, TM	1
Koenig, W	1
Alipour, A; Castro Cabezas, M; Dallinga-Thie, GM; Plokker, HW; Sijmonsma, TP; van Oostrom, AJ; Verseyden, C	1
Backes, JM; Gibson, CA; Moriarty, PM; Ruisinger, JF	1
Scheen, AJ	1
Ai, M; Asztalos, BF; Jones, PH; Otokozawa, S; Schaefer, EJ; Stein, EA; Tanaka, A; Van Himbergen, T	1
Bairaktari, ET; Christogiannis, LG; Elisaf, MS; Filippatos, TD; Kostapanos, MS; Milionis, HJ; Tselepis, AD	1
Koopmans, RP	1
Aso, Y; Inukai, T; Matsumoto, S; Suetsugu, M; Takebayashi, K	1
Bosch, J; Lonn, E; Yusuf, S	1
Narkiewicz, K	1
Akin, KO; Ata, N; Cil, H; Dal, K; Ertugrul, DT; Hokkaomeroglu, MS; Kucukazman, M; Tutal, E; Yalcin, AA; Yavuz, B; Yavuz, BB	1
Cain, VA; Libby, P; Mohanavelu, S; Nissen, SE; Raichlen, JS; Wiviott, SD	1
Agouridis, AD; Elisaf, MS; Kostapanos, MS; Milionis, HJ; Rizos, CV	1
Bailey, KM; Balmforth, AJ; Barth, JH; Copeland, J; Efthymiou, M; Farrin, AJ; Flather, MD; Hall, AS; Jackson, BM; McCormack, T; Nixon, J; Romaine, SP; Whitehead, A	1
Hata, M; Hirayama, A; Minami, K; Sezai, A; Takayama, T; Yoshitake, I	1
Bangit, JR; Batsell, RR; John, S; Molinella, R; Reddy, KJ; Singh, M; Varghese, S; Zaheer, MS	1
Bartholomew, JR; Perez, A	1
Lin, ZP; Shu, PC; Wu, SQ; Zhang, RK; Zhang, ZW	1
Elisaf, MS; Florentin, M; Kostapanos, MS; Kostara, CE; Liberopoulos, EN; Milionis, HJ; Rizos, CV	1
Blumenthal, RS; Harrington, C; Hasan, RK; Horne, A	1
Ikeda, S; Kasai, K; Matsumura, M; Monden, T; Yanagi, K	1
Ai, M; Asztalos, BF; Himbergen, TV; Jones, PH; Nakajima, K; Otokozawa, S; Schaefer, EJ; Stein, E; Thongtang, N	1
Antonsen, L; Egede, R; Hansen, HS; Hansen, KN; Jensen, LO; Junker, A; Thayssen, P	1
Cutchins, C; Cutchins, DC; Gopalagowda, BH; Peiris, AN	1
Eren, MA; Koksal, M; Sabuncu, T; Turan, MN	1
Furman, A; Lopez, JR; Malmstrom, RA; Meier, JL; Schaefer, S	1
Charlton-Menys, V; Dissanayake, S; Durrington, PN; France, MW; Kwok, S; Soran, H; Younis, NN	1
Kataoka, Y; Nicholls, SJ; Uno, K	1
Ahn, YK; Baek, SH; Byun, YS; Cho, KI; Choi, DJ; Choi, SW; Choi, YS; Jang, Y; Jeon, DW; Kim, JY; Kim, KS; Kim, YJ; Lee, SH; Min, PK; Rha, SW	1
Dengler, M; Hammond, BR; Renzi, LM; Roberts, R	1
Boekholdt, SM; Glynn, RJ; Kastelein, JJ; Mora, S; Nordestgaard, BG; Ridker, PM	1
Acbay, O; Celik, O	1
Al-Sarraf, A; Frohlich, J; Li, M; Mattman, A	1
Hu, M; Mak, VW; Tomlinson, B	1
Igase, M; Kido, T; Kohara, K; Miki, T; Nagai, T; Ochi, M; Ochi, N; Tabara, Y	1
Andersen, K; Björnsdóttir, LR; Einarsdóttir, R; Gizurarson, S; Halldórsson, M	1
Diaz, JA; Hawley, AE; Lawrence, DA; Myers, DD; Patterson, KA; Wakefield, TW; Wrobleski, SK; Zhang, X	1
Korlipara, K	1
Fellström, BC; Holdaas, H; Jardine, AG	1
Stein, EA	2
Balligand, JL; Desager, JP; Dessy, C; Feron, O; Massion, P; Pelat, M	1
Capuzzi, DM; Chitra, RR; Cressman, MD; Hutchinson, HG; Morgan, JM; Weiss, RJ	1
Davidson, MH	4
Owen, OG	1
Schuster, H	2
Tuomilehto, J	1
Brewer, HB	1
McKillop, T	1
Caslake, MJ; Chapman, MJ; Daly, E; Day, SP; Durrington, P; Laggner, P; Mackness, M; McTaggart, F; Packard, CJ; Pears, J; Stewart, G	1
Olsson, A	1
Blasetto, JW; Bryzinski, BS; Caplan, RJ; Gold, A; Olsson, GO	1
Avogaro, A	1
Bernini, F; Catapano, AL	1
Schweiger, C	1
Roberts, WC	1
Rosenson, RS	1
Curran, MP; Figgitt, DP; Scott, LJ	1
Durrington, PN; Hamann, A; Kallend, D; Smith, K; Tuomilehto, J	1
Leonard, KA	1
Wooltorton, E	1
Chen, J; Li, D; Mehta, JL; Schaefer, RF	1
Harris, S; Hunninghake, DB; Hutchinson, HG; Kastelein, JJ; Pears, J; Shepherd, J; Stein, EA	1
Cheng, JW	1
Capuzzi, DM; Carey, CM; Cressman, MD; Intenzo, C; Kearney, D; Morgan, JM; Tulenko, T; Walker, K	1
Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH	1
Teramoto, T; Watkins, C	1
McKenney, JM	1
Calza, L; Chiodo, F; Colangeli, V; Legnani, G; Manfredi, R; Pocaterra, D; Tampellini, L	1
Kallend, D; Leiter, LA; Tuomilehto, J	1
Cabezas, MC; Jansen, EH; Plokker, HW; Rabelink, TJ; Stehouwer, CD; van Asbeck, BS; van Kessel, KP; van Oostrom, AJ	1
Frolich, J; Humphries, K; Ignaszewski, A; Imai, C; Samman, A; Straatman, L	1
Antonopoulos, S; Giannoulis, G; Kokkoris, S; Mikros, S; Mylonopoulou, M	1
Gordon, NF; Ranganna, KM; Reddy, RS; Verma, A; Verma, M	1
Borok, GM; Bullano, MF; Gandhi, S; Kamat, S; McDonough, KL; Wertz, DA; Willey, VJ; Yang, GW	1
Kawasaki, A; Kesler, A; Purvin, V; Smith, KH	1
Elisaf, MS; Filippatos, TD; Ganotakis, ES; Gazi, IF; Goudevenos, J; Kostapanos, M; Mikhailidis, DP; Milionis, HJ; Rizos, E	1
Kapur, NK	1
Bennett, MT; Bondy, GP; Johns, KW	1
Askew, V; Auerbach, B; Bainbridge, G; Bratton, LD; Caspers, N; Chen, H; Cheng, XM; Choi, C; Dillon, L; Eberstadt, M; Erasga, N; Hanselman, JC; Harris, MS; Larsen, SD; Lee, C; Lin, Z; Lu, G; Mertz, T; Miller, SR; Olsen, K; Pavlovsky, A; Pfefferkorn, JA; Poel, TJ; Robertson, A; Sekerke, C; Song, Y; Sorenson, RJ; Sun, KL; Trivedi, BK; Unangst, PC	1
Fuller, SH; Merz, T	1
Bar, SL; Frohlich, J; Holmes, DT	1
Blasetto, JW; Davidson, MH; Fox, KM; Gandhi, SK; Ohsfeldt, RL	1
Derdemezis, CS; Elisaf, MS; Filippatos, TD; Kiortsis, DN; Kostapanos, MS; Milionis, HJ; Tselepis, AD	1
Bairaktari, ET; Elisaf, MS; Kostapanos, MS; Kostara, C; Lagos, KG; Milionis, HJ; Saougos, VG	1
Ai, M; Asztalos, BF; Jones, PH; Nakajima, K; Otokozawa, S; Schaefer, EJ; Stein, E	1
Yamamoto, A	1

Reviews

31 review(s) available for fluorobenzenes and Hyperlipidemias

Article	Year
Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin. Clinical interventions in aging, 2014, Volume: 9 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Asian People; Atherosclerosis; China; Coronary Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Young Adult	2014
Lipid-lowering efficacy of rosuvastatin. The Cochrane database of systematic reviews, 2014, Nov-21, Issue:11 Topics: Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2014
Rosuvastatin: efficacy, safety and clinical effectiveness. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:12 Topics: Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2008
Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10 Topics: Angiography; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2008
Lipid lowering for primary prevention. Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670 Topics: Aged; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Meta-Analysis as Topic; Primary Prevention; Proportional Hazards Models; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Treatment Outcome	2009
Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk. Expert review of cardiovascular therapy, 2011, Volume: 9, Issue:11 Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2011
Why do we need a statin trial in hemodialysis patients? Kidney international. Supplement, 2003, Issue:84 Topics: Fluorobenzenes; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Pyrimidines; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Uremia	2003
The power of statins: aggressive lipid lowering. Clinical cardiology, 2003, Volume: 26, Issue:4 Suppl 3 Topics: Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2003
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert opinion on investigational drugs, 2002, Volume: 11, Issue:3 Topics: Clinical Trials as Topic; Fluorobenzenes; Half-Life; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2002
Rosuvastatin--a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients. Cardiology, 2003, Volume: 99, Issue:3 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2003
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia. Diabetes research and clinical practice, 2003, Volume: 61 Suppl 1 Topics: Body Weight; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Fluorobenzenes; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Metformin; Motor Activity; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2003
Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. The American journal of cardiology, 2003, Aug-21, Volume: 92, Issue:4B Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Humans; Hyperlipidemias; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Safety; Sulfonamides	2003
Newer pharmaceutical agents to treat lipid disorders. Current cardiology reports, 2003, Volume: 5, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2003
Statins: how far have we come? A review of rosuvastatin. International journal of clinical practice. Supplement, 2003, Issue:137 Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2003
[Diabetes and multimetabolic syndrome]. Italian heart journal : official journal of the Italian Federation of Cardiology, 2003, Volume: 4 Suppl 7 Topics: Diabetes Mellitus; Fluorobenzenes; Humans; Hypercholesterolemia; Hyperlipidemias; Insulin Resistance; Metabolic Syndrome; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2003
[Rosuvastatin: pharmacologic features]. Italian heart journal : official journal of the Italian Federation of Cardiology, 2003, Volume: 4 Suppl 7 Topics: Animals; Arteriosclerosis; Biotransformation; Cholesterol; Drug Interactions; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2003
[Clinical trials with rosuvastatin: efficacy and safety of its use]. Italian heart journal : official journal of the Italian Federation of Cardiology, 2003, Volume: 4 Suppl 7 Topics: Aged; Anticholesteremic Agents; Clinical Trials as Topic; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides	2003
Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert review of cardiovascular therapy, 2003, Volume: 1, Issue:4 Topics: Drug Interactions; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Metabolic Syndrome; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2003
Rosuvastatin: a review of its use in the management of dyslipidemia. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2004, Volume: 4, Issue:2 Topics: Drug Interactions; Fluorobenzenes; Food-Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Metabolic Clearance Rate; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides	2004
Treatment and prevention of dyslipidemia with rosuvastatin (Crestor). The Nurse practitioner, 2004, Volume: 29, Issue:5 Topics: Administration, Oral; Biological Availability; Clinical Trials as Topic; Drug Monitoring; Fluorobenzenes; Half-Life; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Intestinal Absorption; Metabolic Clearance Rate; Nurse Practitioners; Patient Education as Topic; Patient Selection; Practice Guidelines as Topic; Primary Health Care; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2004
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert opinion on drug safety, 2004, Volume: 3, Issue:6 Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Biomarkers; Cholesterol, LDL; Creatine Kinase; Creatine Kinase, MM Form; Drug Approval; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Incidence; Isoenzymes; Kidney Tubules; Muscular Diseases; Product Surveillance, Postmarketing; Proteinuria; Pyridines; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides	2004
Rosuvastatin in the management of hyperlipidemia. Clinical therapeutics, 2004, Volume: 26, Issue:9 Topics: Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperlipoproteinemia Type II; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides	2004
Review of efficacy of rosuvastatin 5 mg. International journal of clinical practice, 2005, Volume: 59, Issue:1 Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2005
Efficacy and safety of rosuvastatin in treatment of dyslipidemia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2005, May-15, Volume: 62, Issue:10 Topics: Cholesterol, HDL; Cholesterol, LDL; Creatinine; Dose-Response Relationship, Drug; Drug Interactions; Fluorobenzenes; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Proteinuria; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States	2005
A review of the efficacy of rosuvastatin in patients with type 2 diabetes. International journal of clinical practice. Supplement, 2004, Issue:143 Topics: Anticholesteremic Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2004
Statin-associated myasthenia gravis: report of 4 cases and review of the literature. Medicine, 2006, Volume: 85, Issue:2 Topics: Aged; Autoantibodies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myasthenia Gravis; Pravastatin; Pyrimidines; Receptors, Cholinergic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2006
Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:2 Topics: Adolescent; Adult; Age Factors; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Male; Middle Aged; Primary Prevention; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Survival Analysis	2007
The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:2 Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation Mediators; Male; Maximum Tolerated Dose; Program Evaluation; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Sensitivity and Specificity; Sulfonamides	2007
[New statins under clinical development: nisvastatin and rosuvastatin]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3 Topics: Animals; Cholesterol, LDL; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Quinolines; Rosuvastatin Calcium; Sulfonamides	2001
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert opinion on investigational drugs, 2002, Volume: 11, Issue:1 Topics: Clinical Trials as Topic; Drug Therapy, Combination; Fluorobenzenes; Humans; Hyperlipidemias; Hypolipidemic Agents; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2002
Managing dyslipidemia in the high-risk patient. The American journal of cardiology, 2002, Mar-07, Volume: 89, Issue:5A Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States	2002

Trials

32 trial(s) available for fluorobenzenes and Hyperlipidemias

Article	Year
Comparision of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease. Angiology, 2014, Volume: 65, Issue:9 Topics: Arginine; Atorvastatin; Biomarkers; Coronary Angiography; Coronary Stenosis; Down-Regulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Time Factors; Treatment Outcome; Turkey	2014
Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. International journal of cardiology, 2013, Dec-10, Volume: 170, Issue:2 Topics: beta-Cyclodextrins; Cholesterol, LDL; Citrus; Drug Synergism; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Peroxidation; Male; Malondialdehyde; Phosphorylation; Placebos; Plant Extracts; Prospective Studies; Proto-Oncogene Proteins c-akt; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Scavenger Receptors, Class E; Sulfonamides; Triglycerides	2013
Effects of two lipid lowering therapies on immune responses in hyperlipidemic subjects. Life sciences, 2014, Mar-11, Volume: 98, Issue:2 Topics: Antibodies; Azetidines; Cholesterol, LDL; Ezetimibe; Fluorobenzenes; HLA-D Antigens; Humans; Hyperlipidemias; Hypolipidemic Agents; Immune System; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2014
Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. European journal of pharmacology, 2008, Aug-20, Volume: 590, Issue:1-3 Topics: Adult; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin Resistance; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2008
Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. Journal of lipid research, 2009, Volume: 50, Issue:4 Topics: Absorption; Adult; Aged; Atorvastatin; Biomarkers; Cholesterol; Diabetes Complications; Female; Fluorobenzenes; Glycated Serum Albumin; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Phytosterols; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serum Albumin; Sterols; Sulfonamides	2009
Is hsCRP Back on Board? Implications from the JUPITER Trial. Clinical chemistry, 2009, Volume: 55, Issue:2 Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Predictive Value of Tests; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2009
[JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein]. Revue medicale de Liege, 2008, Volume: 63, Issue:12 Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; France; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Practice Guidelines as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States	2008
Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. Journal of cardiovascular pharmacology and therapeutics, 2009, Volume: 14, Issue:1 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoproteins; Aryldialkylphosphatase; Cholesterol, HDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Phenotype; Pyrimidines; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2009
Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. Southern medical journal, 2009, Volume: 102, Issue:4 Topics: C-Reactive Protein; Chemokine CCL2; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Enzyme-Linked Immunosorbent Assay; Epichlorohydrin; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Imidazoles; Male; Middle Aged; Oxidative Stress; Peptide Fragments; Prospective Studies; Pyrimidines; Resins, Synthetic; Retinol-Binding Proteins; Rosuvastatin Calcium; Sulfonamides	2009
Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovascular drugs and therapy, 2009, Volume: 23, Issue:4 Topics: Aged; Alkaline Phosphatase; Bone and Bones; Cohort Studies; Diabetes Mellitus; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vitamin D	2009
Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study). The American journal of cardiology, 2009, Jul-01, Volume: 104, Issue:1 Topics: Aged; Cholesterol, VLDL; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Statistics, Nonparametric; Sulfonamides	2009
A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial. European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2009, Volume: 16, Issue:6 Topics: Aged; Biomarkers; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Practice Guidelines as Topic; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; United Kingdom	2009
[Effects of rosuvastatin on left ventricular cardiac function, arteriosclerotic plaque and high sensitive C-reactive protein in hypertensive patients with mild LDL-C elevation]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2010, Volume: 30, Issue:3 Topics: Aged; Arteriosclerosis; C-Reactive Protein; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ventricular Function, Left	2010
Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. Clinical therapeutics, 2010, Volume: 32, Issue:3 Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; C-Reactive Protein; Drug Therapy, Combination; Fasting; Female; Fluorobenzenes; Greece; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Imidazoles; Insulin; Irbesartan; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Telmisartan; Tetrazoles	2010
A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes. Advances in therapy, 2011, Volume: 28, Issue:2 Topics: C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Japan; Plasminogen Activator Inhibitor 1; Pyrimidines; Quinolines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha	2011
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. The American journal of cardiology, 2011, Feb-01, Volume: 107, Issue:3 Topics: Adiponectin; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus; Female; Fluorobenzenes; Glucose; Glycated Serum Albumin; Glycation End Products, Advanced; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serum Albumin; Sulfonamides; Triglycerides	2011
Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients. International journal of cardiology, 2012, Jul-26, Volume: 158, Issue:3 Topics: Aged; Brachial Artery; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Ultrasonography; Vasodilation	2012
The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients. European journal of internal medicine, 2011, Volume: 22, Issue:3 Topics: Adolescent; Adult; Aged; Antioxidants; Atorvastatin; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Oxidative Stress; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Young Adult	2011
Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia. Atherosclerosis, 2012, Volume: 221, Issue:1 Topics: Aged; Asian People; Biomarkers; Blood Glucose; Blood Urea Nitrogen; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Creatinine; Drug Combinations; Enzymes; Female; Fenofibrate; Fluorobenzenes; Hemoglobins; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Liver; Male; Middle Aged; Muscle, Skeletal; Patient Selection; Pyrimidines; Republic of Korea; Rhabdomyolysis; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome	2012
Low-dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia. Menopause (New York, N.Y.), 2012, Volume: 19, Issue:12 Topics: Aged; Atherosclerosis; Biomarkers; Brachial Artery; C-Reactive Protein; Carotid Artery, Common; Carotid Intima-Media Thickness; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Postmenopause; Pulse Wave Analysis; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vascular Stiffness	2012
Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. The American journal of cardiology, 2003, Jun-01, Volume: 91, Issue:11 Topics: Adolescent; Adult; Cholesterol, HDL; Creatine Kinase; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorobenzenes; Humans; Hyperlipidemias; Hypolipoproteinemias; Lipoproteins; Male; Middle Aged; Niacin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Vasodilation	2003
Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis, 2003, Volume: 171, Issue:2 Topics: Administration, Oral; Adult; Apolipoproteins; Cholesterol; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hyperlipidemias; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pharmacogenetics; Phenotype; Probability; Pyrimidines; Reference Values; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Treatment Outcome; Triglycerides	2003
Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes research and clinical practice, 2004, Volume: 64, Issue:2 Topics: Adult; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2004
Safety of rosuvastatin. The American journal of cardiology, 2004, Oct-01, Volume: 94, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Biomarkers; Child; Cholesterol, LDL; Creatine Kinase; Dose-Response Relationship, Drug; Eye; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney; Liver; Male; Middle Aged; Muscle, Skeletal; Proteinuria; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2004
Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia. Preventive cardiology, 2004,Fall, Volume: 7, Issue:4 Topics: Adult; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Niacin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; United States	2004
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. The American journal of cardiology, 2005, Feb-01, Volume: 95, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2005
Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis. Atherosclerosis, 2006, Volume: 185, Issue:2 Topics: Adult; Antigens, CD; CD11a Antigen; CD11b Antigen; Cell Adhesion Molecules; Chemotaxis, Leukocyte; Coronary Artery Disease; Dietary Fats; Erythrocyte Count; Fluorobenzenes; GPI-Linked Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Interleukin-8; L-Selectin; Leukocytes; Male; Middle Aged; Neutrophils; Oxidative Stress; Platelet Count; Postprandial Period; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vascular Cell Adhesion Molecule-1	2006
Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. The American journal of cardiology, 2005, Nov-01, Volume: 96, Issue:9 Topics: Aged; Biomarkers; C-Reactive Protein; Female; Fluorobenzenes; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Lipoproteins, LDL; Male; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2005
Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Current medical research and opinion, 2006, Volume: 22, Issue:6 Topics: Atorvastatin; Blood Proteins; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2006
Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. European journal of pharmacology, 2008, Jan-14, Volume: 578, Issue:2-3 Topics: Adult; Aged; Biomarkers; Cytokines; Down-Regulation; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Life Style; Lipids; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Pilot Projects; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome	2008
Dose-dependent effect of rosuvastatin treatment on urinary protein excretion. Journal of cardiovascular pharmacology and therapeutics, 2007, Volume: 12, Issue:4 Topics: Alpha-Globulins; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Prospective Studies; Proteinuria; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2007
Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. The American journal of cardiology, 2008, Feb-01, Volume: 101, Issue:3 Topics: Aged; Atorvastatin; Cell Count; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2008

Other Studies

43 other study(ies) available for fluorobenzenes and Hyperlipidemias

Article	Year
Factors involved in rosuvastatin induction of insulin sensitization in rats fed a high fat diet. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2013, Volume: 23, Issue:11 Topics: Adipokines; Adipose Tissue, White; Animals; Diet, High-Fat; Down-Regulation; Endothelium, Vascular; Fluorobenzenes; Glucose Transporter Type 4; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin Resistance; Male; MAP Kinase Signaling System; Overweight; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR gamma; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sirtuin 1; Sulfonamides; Transcription Factors; Vasodilation	2013
Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective. Journal of medical economics, 2013, Volume: 16, Issue:7 Topics: Adult; Atorvastatin; Costs and Cost Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Managed Care Programs; Models, Economic; Myocardial Infarction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; United States	2013
Rosuvastatin escape in a Chinese elderly with hyperlipidemia. Chinese medical journal, 2013, Volume: 126, Issue:18 Topics: Aged; Female; Fluorobenzenes; Humans; Hyperlipidemias; Polymorphism, Genetic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2013
Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients. Biological & pharmaceutical bulletin, 2014, Volume: 37, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperuricemia; Kidney; Male; Middle Aged; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Uric Acid	2014
[Effects of rosuvastatin on arterial stiffness in hyperlipidemia patients]. Zhonghua yi xue za zhi, 2014, Aug-19, Volume: 94, Issue:31 Topics: Ankle Brachial Index; Ankle Joint; Atherosclerosis; Blood Flow Velocity; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Pulsatile Flow; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vascular Stiffness	2014
Comparison of different methods to investigate postprandial lipaemia. The Netherlands journal of medicine, 2009, Volume: 67, Issue:1 Topics: Area Under Curve; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Postprandial Period; Pyrimidines; Regression Analysis; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2009
Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. The American journal of cardiology, 2009, Feb-01, Volume: 103, Issue:3 Topics: Cholesterol; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2009
Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels. Atherosclerosis, 2009, Volume: 205, Issue:1 Topics: Apolipoprotein B-48; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Intestinal Mucosa; Lipoproteins; Liver; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2009
[JUPITER study (2). For now no reason to give statins to more people]. Nederlands tijdschrift voor geneeskunde, 2009, Feb-07, Volume: 153, Issue:6 Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Practice Guidelines as Topic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States	2009
[JUPITER study, more reason to give statins as preventive measure - commentary]. Kardiologia polska, 2009, Volume: 67, Issue:3 Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Comorbidity; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Treatment Outcome	2009
Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. International journal of clinical practice, 2009, Volume: 63, Issue:9 Topics: Adolescent; Adult; Aged; Blood Glucose; Fasting; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Young Adult	2009
Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease. The Annals of thoracic surgery, 2009, Volume: 88, Issue:5 Topics: Anticholesteremic Agents; Coronary Artery Bypass; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Pyrimidines; Radiography; Rosuvastatin Calcium; Saphenous Vein; Sulfonamides; Ultrasonography; Vascular Diseases	2009
Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use. Journal of clinical hypertension (Greenwich, Conn.), 2009, Volume: 11, Issue:12 Topics: Allylamine; Analysis of Variance; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Monitoring; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pulse Therapy, Drug; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides	2009
Interpreting the JUPITER trial: statins can prevent VTE, but more study is needed. Cleveland Clinic journal of medicine, 2010, Volume: 77, Issue:3 Topics: Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Confidence Intervals; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Venous Thromboembolism	2010
New analysis supports expanded use of statins in women. Harvard women's health watch, 2010, Volume: 17, Issue:8 Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Health Knowledge, Attitudes, Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver; Middle Aged; Muscular Diseases; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; United States; Women's Health	2010
Statin therapy in primary prevention: new insights regarding women and the elderly. The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9 Topics: Age Factors; Aged; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sex Factors; Sulfonamides; United States	2010
Alternate day rosuvastatin, an underutilized option in statin intolerant hyperlipidemic patients: a case report and literature review. Tennessee medicine : journal of the Tennessee Medical Association, 2011, Volume: 104, Issue:2 Topics: Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Muscular Diseases; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2011
Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients. The American journal of managed care, 2011, Volume: 17, Issue:8 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United States	2011
Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients. Annals of clinical biochemistry, 2011, Volume: 48, Issue:Pt 6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Apolipoprotein B-100; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reference Values; Regression Analysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult	2011
The relation between serum lipids and lutein and zeaxanthin in the serum and retina: results from cross-sectional, case-control and case study designs. Lipids in health and disease, 2012, Feb-29, Volume: 11 Topics: Adult; Aged; Case-Control Studies; Cross-Sectional Studies; Feeding Behavior; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Lutein; Male; Middle Aged; Pyrimidines; Retina; Rosuvastatin Calcium; Sulfonamides; Xanthophylls; Young Adult; Zeaxanthins	2012
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an inte Journal of the American College of Cardiology, 2012, Apr-24, Volume: 59, Issue:17 Topics: Aged; Apolipoproteins B; Blood Chemical Analysis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Pyrimidines; Reference Values; Risk Assessment; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Treatment Outcome; Triglycerides; United States	2012
Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. Journal of endocrinological investigation, 2012, Volume: 35, Issue:10 Topics: Adult; Blood Glucose; Body Mass Index; Drug Combinations; Female; Fluorobenzenes; Follow-Up Studies; Glucose Intolerance; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Hyperlipidemias; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prognosis; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Testosterone	2012
Use of once-weekly statin in combination with ezetimibe in a patient with mitochondrial disease. BMJ case reports, 2012, Apr-23, Volume: 2012 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Mitochondrial Diseases; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Xanthomatosis	2012
Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenetics and genomics, 2012, Volume: 22, Issue:11 Topics: Adult; Aged; Anticholesteremic Agents; Asian People; Cholesterol, LDL; Female; Fluorobenzenes; Genetic Variation; Humans; Hyperlipidemias; Introns; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2012
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration. Scandinavian journal of public health, 2012, Volume: 40, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Iceland; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reimbursement Mechanisms; Rosuvastatin Calcium; Simvastatin; Social Security; Sulfonamides; Treatment Outcome	2012
Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. Thrombosis research, 2013, Volume: 131, Issue:3 Topics: Animals; Apolipoproteins E; Cell Movement; Disease Models, Animal; Fluorobenzenes; Gene Deletion; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Interleukin-6; Male; Mice; Mice, Knockout; Neutrophils; P-Selectin; Pyrimidines; Rosuvastatin Calcium; Serpin E2; Sulfonamides; Thrombosis; Time Factors; Vena Cava, Inferior; Venous Thrombosis	2013
Statin therapy: rationale for a new agent, rosuvastatin. International journal of clinical practice, 2002, Volume: 56, Issue:5 Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Female; Fluorobenzenes; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2002
Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation, 2003, May-20, Volume: 107, Issue:19 Topics: Animals; Aorta; Apolipoproteins E; Autonomic Nervous System; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Caveolin 1; Caveolins; Cholesterol; Chronobiology Disorders; Electrocardiography, Ambulatory; Fluorobenzenes; Heart Rate; Hyperlipidemias; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2003
52nd Annual Scientific Session of the American College of Cardiology, Chicago, March 30-April 2, 2003. International journal of clinical practice, 2003, Volume: 57, Issue:4 Topics: Anticoagulants; Azetidines; Benzylamines; Cardiology; Cardiovascular Diseases; Chicago; Clinical Trials as Topic; Ezetimibe; Fluorobenzenes; Humans; Hyperlipidemias; Hypolipidemic Agents; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2003
The statin wars. Lancet (London, England), 2003, Nov-01, Volume: 362, Issue:9394 Topics: Clinical Trials as Topic; Drug Approval; Drug Industry; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Periodicals as Topic; Product Surveillance, Postmarketing; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; United Kingdom	2003
The stain wars. Lancet (London, England), 2003, Nov-29, Volume: 362, Issue:9398 Topics: Clinical Trials as Topic; Commerce; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Industry; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Patents as Topic; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides	2003
Two more drugs for dyslipidemia. The American journal of cardiology, 2004, Mar-15, Volume: 93, Issue:6 Topics: Azetidines; Drug Approval; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; United States; United States Food and Drug Administration	2004
Rosuvastatin (Crestor) and rhabdomyolysis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2004, Jul-20, Volume: 171, Issue:2 Topics: Canada; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides	2004
Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis. Journal of cardiovascular pharmacology, 2004, Volume: 44, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteriosclerosis; Benzimidazoles; Biphenyl Compounds; CD40 Antigens; Cholesterol; Drug Synergism; Drug Therapy, Combination; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Matrix Metalloproteinases; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrimidines; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2	2004
Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS (London, England), 2005, Jul-01, Volume: 19, Issue:10 Topics: Adult; Antiretroviral Therapy, Highly Active; Cholesterol; Female; Fluorobenzenes; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrimidines; Reverse Transcriptase Inhibitors; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2005
Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2005, Volume: 24, Issue:8 Topics: Aged; Aged, 80 and over; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Graft Rejection; Graft Survival; Heart Transplantation; Humans; Hyperlipidemias; Male; Middle Aged; Postoperative Complications; Prospective Studies; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Survival Rate; Treatment Outcome	2005
Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis, 2006, Volume: 184, Issue:1 Topics: Fatty Liver; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2006
Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy, 2006, Volume: 26, Issue:4 Topics: Adult; Cholesterol, LDL; Drug Evaluation; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; National Health Programs; Program Evaluation; Pyrimidines; Retrospective Studies; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; United States	2006
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids in health and disease, 2007, Jun-13, Volume: 6 Topics: Adult; Aged; Anti-Retroviral Agents; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Protease Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides	2007
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors. Bioorganic & medicinal chemistry letters, 2007, Aug-15, Volume: 17, Issue:16 Topics: Animals; Cricetinae; Dose-Response Relationship, Drug; Drug Design; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver; Models, Molecular; Molecular Structure; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Structure-Activity Relationship; Sulfonamides	2007
Elevated serum transaminase levels resulting from concomitant use of rosuvastatin and amiodarone. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Sep-01, Volume: 64, Issue:17 Topics: Aged; Alanine Transaminase; Amiodarone; Anti-Arrhythmia Agents; Aortic Valve; Aortic Valve Stenosis; Aspartate Aminotransferases; Drug Interactions; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2007
Asymptomatic hypothyroidism and statin-induced myopathy. Canadian family physician Medecin de famille canadien, 2007, Volume: 53, Issue:3 Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypothyroidism; Male; Middle Aged; Muscular Diseases; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Thyroid Function Tests; Thyrotropin	2007
Effectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data. International journal of clinical practice, 2007, Volume: 61, Issue:10 Topics: Aged; Cholesterol, LDL; Cohort Studies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Multivariate Analysis; Pyrimidines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2007